The Oral Peptide Opportunity Hiding in Plain Sight

Osteoporosis hospitalizes more women each year than heart attacks, strokes, and breast cancer combined. Hip fractures carry a 20% mortality rate within twelve months - deadlier than many cancers. Yet no new drug has been approved by the FDA since 2019, and the most effective treatments remain locked behind daily injections that fewer than one in four eligible patients ever start. The market hasn't lacked efficacy. It has lacked convenience.

Entera Bio (NASDAQ: ENTX) may be on the verge of solving that problem. The company's lead candidate, EB613, is designed to be the first oral anabolic tablet for osteoporosis — delivering the same bone-building hormone as Eli Lilly's Forteo, which generated $1.7 billion in peak annual sales, in a simple tablet treatment. For a company whose entire market capitalization sits at roughly $54 million, the gap between what has been clinically demonstrated and how the market has priced it is difficult to reconcile.

In a 161-patient Phase 2 trial published in the Journal of Bone and Mineral Research, EB613 produced statistically significant bone mineral density gains across the spine, total hip, and femoral neck within just six months. At the spine, results were closely comparable to published Forteo data. But at the hip — where fractures are most lethal — the oral tablet outperformed dramatically.

Beyond the headline numbers, EB613 demonstrated an unexpected dual mechanism: simultaneously building new bone and reducing bone breakdown — a pharmacological profile not typically observed with injectable teriparatide. Data presented at ASBMR 2025 further confirmed significant effects on both trabecular and cortical bone after just six months, with cortical improvements comparable to the best-in-class injectable anabolics.

The regulatory path has cleared in parallel. In July 2025, the FDA agreed that Entera could use BMD as the primary endpoint for its Phase 3 registrational trial. In December 2025, the agency went further, broadly qualifying total hip BMD as a validated surrogate endpoint for all new osteoporosis therapies — eliminating the need for years-long fracture studies and substantially de-risking the approval pathway.

At roughly $54 million, Entera's entire market capitalization is ~5% of what AstraZeneca paid for Amolyt - a single injectable asset (focused on hypoparathyroidism) that had not completed Phase 3 yet, with a presumably smaller patient population than the one Entera’s lead candidate it targeting.

While EB613 remains the most advanced program, Entera's hypoparathyroidism pipeline has quietly matured into one of the company's most compelling value drivers. Hypoparathyroidism is a lifelong condition requiring decades of hormone replacement — and the market has been commercially validated at scale. Ascendis Pharma's Yorvipath, the only approved daily injectable PTH replacement, generated over €100 million in a single quarter and propelled Ascendis's market cap from ~$4 billion to over $12 billion. As noted, AstraZeneca paid $1.05 billion to acquire Amolyt Pharma for an injectable that hadn't finished Phase 3.

In December 2025, Entera reported preclinical data showing its long-acting oral PTH candidate sustained calcium elevation for more than three days from a single tablet — supporting a commercially viable once-daily regimen. In February 2026, OPKO Health expanded its partnership with Entera to accelerate the program toward an IND filing in late 2026, with the two companies sharing development costs equally. The program holds orphan drug designation in both the U.S. and EU.

The platform underlying both programs — Entera's proprietary N-Tab® technology — has seen validation now across multiple peptide targets at various stages, with over 250 patients dosed safely. Beyond osteoporosis and hypoparathyroidism, Entera is advancing oral oxyntomodulin (a dual GLP-1/glucagon agonist for obesity) and oral GLP-2 (for short bowel syndrome) in partnership with OPKO, positioning the platform across several of biopharma's most active investment themes.

What makes the current moment particularly notable is the density of near-term milestones - which tends to be a strong excitement driver for companies of this size. Several events are expected to land in quick succession over the coming months:

The broader context reinforces the thesis. The oral peptide therapeutics market is projected to approach $20 billion by 2030. Pfizer paid $150 million upfront in December 2025 for a Phase 1 oral GLP-1 asset from YaoPharma — a deal whose total potential value of $2 billion dwarfs Entera's entire market capitalization. Johnson & Johnson's pursuit of Protagonist Therapeutics further signals how aggressively large pharma is moving into peptide space.

Drug development carries inherent risk - Phase 3 outcomes are never guaranteed, and a company with a cash runway through mid-Q3 2026 will need to address funding. But when Phase 2 data, FDA regulatory alignment, commercial market validation, and a compressed valuation converge simultaneously, the asymmetry deserves attention. The question for Entera may not be whether the science works — Phase 2 already answered that - but whether the market recalibrates before the catalysts land.

=

=

<sub>Legal Disclaimers, Terms & Disclosures: 

By using CapNotes, any related brands thereof, and any affiliated or partner websites operated under the Wall Street Wire Network (collectively referred to as “Services”), you acknowledge that any and all Services provided are for informational and entertainment purposes only and do not constitute a recommendation for any particular stock, company, investment, commodity, security, transaction, or any other method of trading featured anywhere on CapNotes or affiliated platforms. CapNotes does not guarantee the accuracy, completeness, or timeliness of the information or Services provided. Views and opinions presented through the Services, whether expressed by contributors, columnists, external partners, or employees, are not specifically endorsed by CapNotes or the Wall Street Wire Network, and neither entity accepts responsibility or liability for any actions, financial or otherwise, taken directly or indirectly as a result of engaging with any of the Services offered.</sub>

_{CapNotes, its employees, operator, partners, affiliates, and any other representatives will not, either directly or indirectly, be held liable, accountable, or responsible in any capacity to you or to any third party for any errors, inaccuracies, or omissions from the Services, including but not limited to market quotes, rumors, unverified chatter, financial data, and news reports; for any interruptions, delays, or transmission errors affecting the availability or accuracy of the Services; or for any damages or losses arising from or related to the use of, reliance on, or inability to access the Services. Some content published by CapNotes may reference market rumors, speculative chatter, or unconfirmed reports. Readers should be aware that while such unofficial information may be associated with market volatility, price movements based on speculative or incomplete data are subject to change rapidly upon further clarification or the release of official news or filings.}

_{CapNotes reserves the right at any time to modify any part of its Terms of Service or any portion of the Services, including but not limited to the removal or addition of content, features, contributors, or affiliated content providers, or the introduction of any associated fees or usage conditions. Such changes will take effect immediately upon their publication across the Services and will apply to all users from the time of posting. Please note that trading in foreign currencies, stocks, options, and other securities involves substantial risk and may result in significant financial losses. Neither CapNotes nor its staff recommends that you buy, sell, or hold any security, and no part of the Services constitutes personalized investment advice. All information provided through the Services is general commentary intended for informational and entertainment use only. CapNotes disclaims any liability for loss or damage, including without limitation any loss of capital, profit, or opportunity, that may arise directly or indirectly from use of or reliance on the information contained within the Services. We encourage all users to conduct their own due diligence and consult with a certified financial advisor or licensed professional before making any financial decisions.}

_{Content produced by or for CapNotes may not be reproduced, republished in full, or redistributed in any form without prior written permission from CapNotes or the Wall Street Wire Network, as applicable.}

_{This content is a form of paid promotional content and advertising. Wall Street Wire has receives cash compensation from Entera Bio Ltd for promotional media services which we provide on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire alongside the full disclaimers and disclosures this content is subject to are available wallstwire.ai/disclosures. We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. This article was not reviewed or approved by the issuer prior to publication and should not be considered an official communication by it.}